| 000 | 01622 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516151339.0 | ||
| 264 | 0 | _c20140304 | |
| 008 | 201403s 0 0 eng d | ||
| 022 | _a1552-4604 | ||
| 024 | 7 |
_a10.1002/jcph.102 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Xuejun | |
| 245 | 0 | 0 |
_aPopulation pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacology _cJul 2013 |
||
| 300 |
_a721-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aPolycythemia Vera _xdrug therapy |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 |
_aPyrazoles _xadministration & dosage |
| 650 | 0 | 4 | _aPyrimidines |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xdrug therapy |
| 700 | 1 | _aWilliams, William V | |
| 700 | 1 | _aSandor, Victor | |
| 700 | 1 | _aYeleswaram, Swamy | |
| 773 | 0 |
_tJournal of clinical pharmacology _gvol. 53 _gno. 7 _gp. 721-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/jcph.102 _zAvailable from publisher's website |
| 999 |
_c22754881 _d22754881 |
||